# AZD5863

Source: https://onco.cc/drugs/azd5863/  
OnCo record `azd5863` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD5863 is an experimental bispecific antibody from AstraZeneca in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and oesophageal cancer, aimed at Claudin 18.2 and CD3.

## Summary

AZD5863 is a bispecific antibody developed by AstraZeneca. Its targets are Claudin 18.2 and CD3 (the sponsor names CLDN18.2 x CD3). The sponsor states: T cell-engaging bispecific antibody that binds Claudin 18.2 on tumour cells and CD3 on T cells, bridging them to drive immune-mediated tumour cell killing. ClinicalTrials.gov describes the intervention as: T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumour cells and CD3 on T cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and oesophageal cancer. The largest, NCT06005493, plans to enrol 280 participants with primary completion expected 2027-07-16. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: bispecific antibody
- Mechanism: T cell-engaging bispecific antibody that binds Claudin 18.2 on tumour cells and CD3 on T cells, bridging them to drive immune-mediated tumour cell killing.

## Sources

- ClinicalTrials.gov: trials of AZD5863: https://clinicaltrials.gov/search?intr=AZD5863

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [CD3](https://onco.cc/targets/cd3/), [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06005493/)

---
JSON: https://onco.cc/api/v1/entities/azd5863.json